Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2005 1
2006 2
2007 6
2008 3
2009 5
2010 2
2011 4
2012 6
2013 6
2014 5
2015 9
2016 11
2017 4
2018 6
2019 4
2020 4
2021 7
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

80 results
Results by year
Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: mittra e. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: mittra e. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE.
Mittra ES. Mittra ES. AJR Am J Roentgenol. 2018 Aug;211(2):278-285. doi: 10.2214/AJR.18.19953. Epub 2018 Jun 27. AJR Am J Roentgenol. 2018. PMID: 29949416 Review.
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
McClellan K, Chen EY, Kardosh A, Lopez CD, Del Rivero J, Mallak N, Rocha FG, Koethe Y, Pommier R, Mittra E, Pegna GJ. McClellan K, et al. Among authors: mittra e. Cancers (Basel). 2022 Sep 29;14(19):4769. doi: 10.3390/cancers14194769. Cancers (Basel). 2022. PMID: 36230691 Free PMC article. Review.
Clinically Approved Nanoparticle Imaging Agents.
Thakor AS, Jokerst JV, Ghanouni P, Campbell JL, Mittra E, Gambhir SS. Thakor AS, et al. Among authors: mittra e. J Nucl Med. 2016 Dec;57(12):1833-1837. doi: 10.2967/jnumed.116.181362. Epub 2016 Oct 13. J Nucl Med. 2016. PMID: 27738007 Free PMC article. Review.
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E; NETTER-1 study group. Strosberg J, et al. Among authors: mittra e. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2372-2382. doi: 10.1007/s00259-020-04709-x. Epub 2020 Mar 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123969 Free PMC article. Clinical Trial.
PD-1 Blockade-induced Inflammatory Arthritis.
Nobashi T, Mittra E. Nobashi T, et al. Among authors: mittra e. Radiology. 2018 Dec;289(3):616. doi: 10.1148/radiol.2018181532. Epub 2018 Oct 2. Radiology. 2018. PMID: 30277446 No abstract available.
Uncommon causes of thyrotoxicosis.
Mittra ES, Niederkohr RD, Rodriguez C, El-Maghraby T, McDougall IR. Mittra ES, et al. J Nucl Med. 2008 Feb;49(2):265-78. doi: 10.2967/jnumed.107.041202. Epub 2008 Jan 16. J Nucl Med. 2008. PMID: 18199610 Free article. Review.
PET Imaging of Skull Base Neoplasms.
Mittra ES, Iagaru A, Quon A, Fischbein N. Mittra ES, et al. PET Clin. 2007 Oct;2(4):489-510. doi: 10.1016/j.cpet.2008.05.006. Epub 2008 Oct 10. PET Clin. 2007. PMID: 27158109 Review.
80 results